Today: 19 April 2026
Vodafone share price rises on Egypt spectrum buy as investors brace for May results
9 February 2026
1 min read

Vodafone share price rises on Egypt spectrum buy as investors brace for May results

London, February 9, 2026, 09:19 GMT — Regular session

  • Vodafone stock climbed roughly 1.9% to trade close to 112.6 pence early in the London session.
  • Company says it will begin Vodafone Egypt spectrum payments in FY26, kicking off with $100 million.
  • Cash flow remains in the spotlight, with Germany’s momentum drawing attention and all eyes on the May 12 FY26 results date.

Vodafone (VOD.L) shares climbed Monday, gaining around 1.9% to 112.6 pence by 09:19 GMT, after the telecom company announced that its Egypt unit is set to pick up more mobile spectrum.

Spectrum is on the agenda again in Egypt, with the government pressing mobile carriers into a fresh, multi-year airwaves plan. Over the weekend, Egypt’s cabinet announced a $3.5 billion deal to distribute 410 megahertz of new spectrum to the country’s four mobile operators.

Vodafone Group Public Limited Company faces a different dilemma: the balance sheet, not just market exposure. Investors are tracking whether gains in Africa are enough to counter hefty network investments and a German rebound that remains tangled.

Vodafone announced Vodafone Egypt picked up 2×10 MHz of 1,800 MHz spectrum, agreeing to pay in four annual instalments starting with a $100 million outlay—roughly 84 million euros—in fiscal 2026. According to the company, it plans to record an extra $350 million as a spectrum intangible asset. There’s also a mention of a subsequent phase involving 3,500 MHz spectrum, plus renewal of 2,600 MHz licences.

That’s the sector calculus: add capacity, expect to spend more. Spectrum typically hits as a cash outflow up front—hoping eventually it pays off in data usage and better pricing.

Vodafone posted its latest quarterly update last week, highlighting robust gains in Turkey and Africa, though Germany still has investors divided. “Every quarter customer experience goes one step higher,” Chief Executive Margherita Della Valle told reporters. Still, she noted, “the market remains competitive.” Reuters

“Germany remains Vodafone’s toughest nut to crack,” wrote Aarin Chiekrie, equity analyst at Hargreaves Lansdown, in a note following the update. Hargreaves Lansdown

Vodafone stuck to a straightforward line: “We maintained good service revenue momentum in the third quarter across both Europe and Africa,” Della Valle said in the company’s Q3 materials. Vodafone

The bear case stands out. When spectrum and network costs outpace gains in service revenue—or if Germany’s rebound falters again—free cash flow takes the hit. That’s the key number for equity holders, since it’s what’s left after capital expenditures.

Investors are watching May 12, when Vodafone will release its FY26 results and lay out cash flow and capital return guidance for the coming year.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Rolls-Royce share price jumps in London on buyback update as Feb 26 results loom
Previous Story

Rolls-Royce share price jumps in London on buyback update as Feb 26 results loom

Standard Chartered stock nudges higher after ex-UBS hire as Feb 24 results loom
Next Story

Standard Chartered stock nudges higher after ex-UBS hire as Feb 24 results loom

Go toTop